

MEDIMMUNE INC /DE  
Form 8-K  
April 20, 2006

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D. C. 20549**

**Form 8-K  
CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported)

April 20, 2006

**MedImmune, Inc.**

*(Exact name of registrant as specified in its charter)*

**Delaware**  
*(State or other  
jurisdiction of  
incorporation or  
organization)*

**0-19131**  
*(Commission File No.)*

**52-1555759**  
*(I.R.S. Employer  
Identification No.)*

**One MedImmune Way, Gaithersburg, MD 20878**  
*(Address of principal executive offices) (Zip Code)*

*Registrant's telephone number, including area code (301) 398-0000*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 2.02. Results of Operations and Financial Condition.**

On April 20, 2006, MedImmune, Inc. (the Company ) issued a press release announcing the Company s results as of and for the first quarter ended March 31, 2006, and will conduct a previously announced, publicly available conference call to discuss those results. The press release provides an update to the Company s expectations for 2006 from the information previously disclosed in the Company s Annual Report on Form 10-K for the year ended December 31, 2005. A copy of the Company s press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is hereby furnished in its entirety pursuant to Item 2.02.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

See the attached Exhibit Index.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MedImmune, Inc.**

By: /s/ William C. Bertrand, Jr.

William C. Bertrand, Jr.

Senior Vice President, General Counsel  
and Secretary

Date: April 20, 2006

---

**EXHIBIT INDEX**

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
99.1	Press Release dated April 20, 2006, titled MedImmune Reports Financial Results for First Quarter 2006